knowledge -WSS

knowledge

author：leisure time 2025-09-06 03:56:11 - browse：34

Sutter Health Palo Alto Medical Foundation facilities. health tech coverage from STAT — Adobe

When Sutter Health was on trial for anticompetitive conduct in 2022, the San Francisco jury missed out on some crucial details. They didn’t hear, for example, how its former finance chief said the system would make an extra $200 million per year by making insurers contract with all of its hospitals instead of just a few. Or how its former CEO said, “Related to the health plans, we force them to pay us more.”

That evidence was indeed relevant, and the judge erred by not allowing it to be presented during the month-long trial that concluded in March 2022, a U.S. appeals court wrote in its ruling on Tuesday. The Ninth Circuit panel overturned Sutter’s win in the class-action case alleging that Sutter used its market power to drive up health care costs across the region by more than $400 million. Tuesday’s decision means the case will likely get a second trial.

“Effectively, the appellate court said the jury was tainted,” said Matthew Cantor, lead counsel for the plaintiffs. “So the jury’s verdict is discarded.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： David Sabatini, ex

WSS

RaDonda Vaught to speak at CommonSpirit event on patient safety

PBM reforms clear House panel

PBM reforms clear House panel

Why getting cancer drugs just got harder for rural patients

FDA's Woodcock to retire early next year

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Wikipedia

New air purifier tech could be key to improving indoor air quality

World's first CRISPR

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Wegovy, Zepbound and weight loss drugs that preserve muscle

Wildfire smoke exposes gaps in outdoor worker protections

FogPharma raises $145 million in rare Series E round

Cancer drug shortages should be causing more outrage

Covid isolation guidance eased by the CDC

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

entertainment

Morphosys mixed study results for blood cancer drug

Medical device lobby: We're tired of waiting on Medicare coverage

Congress must reauthorize a committee to support older Americans

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

A daunting task: navigating dual Medicare, Medicaid eligibility

Biotech companies concerned about China biosecurity crackdown

hotspot

Wikipedia

focus

hotspot